IL2 and systemic lupus erythematosus: To evaluate the incidence of infection in SLE patients treated with Ld-IL2 therapy, we retrospectively assessed 665 SLE patients admitted to Peking University Peoples Hospital (Beijing, China) from December 2016 to August 2018, including 446 patients treated with standard of care (corticosteroids and conventional immunosuppressive agents) as non-IL-2 group and 219 patients treated standard of care plus 3 cycles of Ld-IL2 as IL-2 group (Fig 1A).